Tags

Type your tag names separated by a space and hit enter

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Antimicrob Agents Chemother. 2016 10; 60(10):6050-9.AA

Abstract

There are contrasting data in the literature about antituberculosis plasma drug concentrations in HIV-1-coinfected patients. We report the pharmacokinetics of rifampin, isoniazid, and pyrazinamide in a cohort of patients being treated for active tuberculosis, the majority of whom were coinfected with HIV-1 and had commenced antiretroviral therapy within 2 months of starting antituberculosis treatment. We also examined the association between antituberculosis drug concentrations and reported drug side effects at the 2-month clinical review. One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands. Pharmacokinetic parameters were determined for each patient by using nonlinear mixed-effects models. HIV-1-coinfected patients had lower clearance rates for rifampin (21% decrease) and isoniazid (23% decrease) than HIV-1-uninfected patients, with resulting higher areas under the concentration-time curve from 0 to 24 h (AUC0-24) and maximum concentrations of drug in serum (Cmax). Antiretroviral therapy (ART) that included double-standard-dose lopinavir/ritonavir further lowered rifampin clearance, by 46%, and increased the AUC0-24 The current uniform dosing (per kilogram of body weight) across WHO weight bands was associated with a trend of decreased pharmacokinetic exposures for the lowest weight band. Use of fat-free mass as opposed to total body weight for allometric scaling of clearance significantly improved the model. Ambulant HIV-1-coinfected patients, the majority of whom were coprescribed ART, did not have reduced antituberculosis drug concentrations compared to HIV-1-uninfected patients.

Authors+Show Affiliations

Department of Medicine, Imperial College, London, United Kingdom Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.Department of Medicine, Imperial College, London, United Kingdom Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa Department of Medicine, University of Cape Town, Cape Town, South Africa.Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.Department of Medicine, Imperial College, London, United Kingdom Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa Department of Medicine, University of Cape Town, Cape Town, South Africa Francis Crick Institute Mill Hill Laboratory, London, United Kingdom.Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa paolo.denti@uct.ac.za.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27480859

Citation

Rockwood, Neesha, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrobial Agents and Chemotherapy, vol. 60, no. 10, 2016, pp. 6050-9.
Rockwood N, Meintjes G, Chirehwa M, et al. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrob Agents Chemother. 2016;60(10):6050-9.
Rockwood, N., Meintjes, G., Chirehwa, M., Wiesner, L., McIlleron, H., Wilkinson, R. J., & Denti, P. (2016). HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrobial Agents and Chemotherapy, 60(10), 6050-9. https://doi.org/10.1128/AAC.00480-16
Rockwood N, et al. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrob Agents Chemother. 2016;60(10):6050-9. PubMed PMID: 27480859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. AU - Rockwood,Neesha, AU - Meintjes,Graeme, AU - Chirehwa,Maxwell, AU - Wiesner,Lubbe, AU - McIlleron,Helen, AU - Wilkinson,Robert J, AU - Denti,Paolo, Y1 - 2016/09/23/ PY - 2016/03/03/received PY - 2016/07/20/accepted PY - 2016/8/3/entrez PY - 2016/8/3/pubmed PY - 2017/8/19/medline SP - 6050 EP - 9 JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 60 IS - 10 N2 - There are contrasting data in the literature about antituberculosis plasma drug concentrations in HIV-1-coinfected patients. We report the pharmacokinetics of rifampin, isoniazid, and pyrazinamide in a cohort of patients being treated for active tuberculosis, the majority of whom were coinfected with HIV-1 and had commenced antiretroviral therapy within 2 months of starting antituberculosis treatment. We also examined the association between antituberculosis drug concentrations and reported drug side effects at the 2-month clinical review. One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands. Pharmacokinetic parameters were determined for each patient by using nonlinear mixed-effects models. HIV-1-coinfected patients had lower clearance rates for rifampin (21% decrease) and isoniazid (23% decrease) than HIV-1-uninfected patients, with resulting higher areas under the concentration-time curve from 0 to 24 h (AUC0-24) and maximum concentrations of drug in serum (Cmax). Antiretroviral therapy (ART) that included double-standard-dose lopinavir/ritonavir further lowered rifampin clearance, by 46%, and increased the AUC0-24 The current uniform dosing (per kilogram of body weight) across WHO weight bands was associated with a trend of decreased pharmacokinetic exposures for the lowest weight band. Use of fat-free mass as opposed to total body weight for allometric scaling of clearance significantly improved the model. Ambulant HIV-1-coinfected patients, the majority of whom were coprescribed ART, did not have reduced antituberculosis drug concentrations compared to HIV-1-uninfected patients. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/27480859/HIV_1_Coinfection_Does_Not_Reduce_Exposure_to_Rifampin_Isoniazid_and_Pyrazinamide_in_South_African_Tuberculosis_Outpatients_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=27480859 DB - PRIME DP - Unbound Medicine ER -